NCT07343479尚未招募2 期
A Clinical Study of Sac-TMT for Injection Combined With Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) ± Radiotherapy in Subjects With EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer and Brain Metastasis Who Have Failed Prior EGFR-TKI Treatment
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- 6-month PFS rate
研究概览
简要总结
This is a prospective, open-label, multi-center, single-arm clinical trial
详细描述
The purpose of this study is to assess the efficacy and safety of sac-TMT combined with third-generation EGFR-TKI with/without intracranial radiotherapy in subjects with EGFR-mutated NSCLC and brain metastasis who have failed prior EGFR-TKI treatment. Eligible subjects will receive sac-TMT (4 mg/kg, twice weekly (Q2W)) + third-generation EGFR-TKI ± intracranial radiotherapy. The decision to initiate intracranial radiotherapy will be determined by the investigator based on the patient's clinical condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 and ≤ 75 years at the time of signing the informed consent form (ICF), regardless of gender;
- •Histologically or cytologically confirmed non-squamous NSCLC, and metastatic (Stage IV);
- •Confirmed EGFR sensitizing mutation including exon 19 deletion (19-Del) or exon 21 point mutation (L858R);
- •Subject has previously received EGFR-TKI therapy for locally advanced or metastatic disease and has experienced radiological PD;
- •Subjects with new or previously diagnosed brain metastasis confirmed by contrast-enhanced cranial MRI;
- •ECOG performance status scale of 0 or 1;
- •Life expectancy ≥ 12 weeks;
- •Adequate organ and bone marrow function;
排除标准
- •Tumor histology or cytology confirms combined small cell lung cancer (SCLC), neuroendocrine carcinoma, carcinosarcoma components, or squamous cell carcinoma;
- •Known leptomeningeal metastases;
- •Other malignant tumors within 3 years prior to the first dose (except for tumors cured by local treatment, such as basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, etc.);
- •Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to >470 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention;
- •Uncontrolled systemic diseases as judged by the investigators;
- •Clinically severe pulmonary impairment due to concurrent lung disorders, including but not limited to any underlying lung disorder (e.g., pulmonary embolism within 3 months before the first dose, severe asthma, severe chronic obstructive pulmonary disease, restrictive pulmonary disease, pleural effusion, etc.) or any autoimmune, connective tissue, or inflammatory disease that may involve the lungs (i.e., rheumatoid arthritis, sicca syndrome, sarcoidosis, etc.), or prior pneumonectomy;
- •Subjects with active chronic inflammatory bowel disease, gastrointestinal obstruction, severe ulcer, gastrointestinal perforation, intra-abdominal abscess, or acute gastrointestinal hemorrhage;
- •History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease;
- •Active infection requiring systemic therapy;
- •Active hepatitis B [hepatitis B surface antigen (HBsAg) positive, requiring hepatitis B virus deoxyribonucleic acid (HBV-DNA) testing; HBV-DNA ≥500 IU/mL or above the lower limit of detection, whichever is higher] or hepatitis C [hepatitis C antibody positive, and hepatitis C virus ribonucleic acid (HCV-RNA) above the lower limit of detection];
- •Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection;
- •History of allogeneic tissue/solid organ transplant.
研究组 & 干预措施
sac-TMT plus EGFR-TKI
Experimental
Sacituzumab tirumotecan combined with third-generation EGFR-TKI with or without intracranial radiotherapy
干预措施: sac-TMT plus EGFR-TKI (Drug)
结局指标
主要结局
6-month PFS rate
时间窗: 6 months post treatment initiation date (maximum follow-up of 36 months)
6-month PFS rate as assessed by the investigators according to RECIST v1.1.
次要结局
- Overall ORR and DCR(From initiation of treatment to disease progression or death from any cause, whichever occurs first (maximum follow-up of 36 months))
- DOR(From first disease response until tumor progression (maximum follow-up of 36 months).)
- OS(From treatment initiation to death due to any cause or last day of contact, whichever occurred first (maximum follow-up of 36 months))
- Safety endpoints(From first dose of study treatment until 30 days after the last dose, assessed up to 36 months.)
研究者
Fan Yun, MD
Director of the Department of Thoracic Oncology, Zhejiang Cancer Hospital
Zhejiang Cancer Hospital
研究点 (1)
Loading locations...
相似试验
招募中
3 期
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011)2024-516834-36-00Merck Sharp & Dohme LLC189
招募中
2 期
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaThymic CarcinomaNCT07324629Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.30
招募中
3 期
A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036)2025-521514-26-00Merck Sharp & Dohme LLC45
Enrolling By Invitation
不适用
Persona SoluTion PPS Femur PMCFNCT07286513Zimmer Biomet200
招募中
2 期
TRAP-BTC
Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer2023-505722-33-00Institut fuer Klinische Krebsforschung IKF GmbH24